Are PPD and inVentiv the next CROs slated for IPOs?; Venn signs on to run an EU trial;

> PPD and inVentiv Health are among the last big CROs that haven't gone public. Outsourcing-Pharma takes a look at their businesses and the odds either will take the plunge on an IPO. Story

> CRO Venn Life Sciences signed a $1.8 million deal to run a European trial for an undisclosed U.S. drug developer. More

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.